Literature DB >> 26270409

Usefulness of Multigene Testing: Catching the Train That's Left the Station.

Elizabeth M Swisher1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26270409     DOI： 10.1001/jamaoncol.2015.2699

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  11 in total

1.  Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.

Authors:  Julia R Trosman; Christine B Weldon; Michael P Douglas; Allison W Kurian; R Kate Kelley; Patricia A Deverka; Kathryn A Phillips
Journal:  J Natl Compr Canc Netw       Date:  2017-02-10       Impact factor: 11.908

2.  Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.

Authors:  Julia R Trosman; Christine B Weldon; Michael P Douglas; Patricia A Deverka; John B Watkins; Kathryn A Phillips
Journal:  Value Health       Date:  2017-01       Impact factor: 5.725

3.  Outcomes of retesting BRCA negative patients using multigene panels.

Authors:  Siddhartha Yadav; Ashley Reeves; Sarah Campian; Amy Paine; Dana Zakalik
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

4.  EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.

Authors:  James D Chambers; Cayla J Saret; Jordan E Anderson; Patricia A Deverka; Michael P Douglas; Kathryn A Phillips
Journal:  Int J Technol Assess Health Care       Date:  2017-10-25       Impact factor: 2.188

5.  Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer.

Authors:  J Brian Szender; Jasmine Kaur; Katherine Clayback; Mollie L Hutton; June Mikkelson; Kunle Odunsi; Cara Dresbold
Journal:  Int J Gynecol Cancer       Date:  2018-01       Impact factor: 3.437

6.  Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences.

Authors:  Allison W Kurian; Christopher R Friese; Irina Bondarenko; Reshma Jagsi; Yun Li; Ann S Hamilton; Kevin C Ward; Steven J Katz
Journal:  JAMA Oncol       Date:  2017-03-01       Impact factor: 33.006

7.  Early-onset triple-negative breast cancer in multiracial/ethnic populations: Distinct trends of prevalence of truncation mutations.

Authors:  Qian Liu; Song Yao; Hua Zhao; Qiang Hu; Marilyn L Kwan; Janise M Roh; Christine B Ambrosone; Lawrence H Kushi; Song Liu; Qianqian Zhu
Journal:  Cancer Med       Date:  2019-03-12       Impact factor: 4.452

8.  Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome.

Authors:  Tomoko Yoshihama; Akira Hirasawa; Kokichi Sugano; Teruhiko Yoshida; Mineko Ushiama; Arisa Ueki; Tomoko Akahane; Yoshiko Nanki; Kensuke Sakai; Takeshi Makabe; Wataru Yamagami; Nobuyuki Susumu; Kaori Kameyama; Kenjiro Kosaki; Daisuke Aoki
Journal:  Int Cancer Conf J       Date:  2020-10-09

9.  Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer.

Authors:  Akira Hirasawa; Issei Imoto; Takuya Naruto; Tomoko Akahane; Wataru Yamagami; Hiroyuki Nomura; Kiyoshi Masuda; Nobuyuki Susumu; Hitoshi Tsuda; Daisuke Aoki
Journal:  Oncotarget       Date:  2017-11-28

10.  Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.

Authors:  Jin-Sun Ryu; Hye-Young Lee; Eun Hae Cho; Kyong-Ah Yoon; Min-Kyeong Kim; Jungnam Joo; Eun-Sook Lee; Han-Sung Kang; Seeyoun Lee; Dong Ock Lee; Myong Cheol Lim; Sun-Young Kong
Journal:  Cancer Sci       Date:  2020-09-02       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.